Cancer-Killing virus joins forces with chemo to fight tough lung cancer

NCT ID NCT07136285

Recruiting now Disease control Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 16 times

Summary

This study tests a new treatment for advanced small cell lung cancer that has stopped responding to standard platinum chemotherapy. The treatment combines an oncolytic virus (Olvi-Vec) with a platinum-based chemo and etoposide. The goal is to see if this combination is safe and can shrink tumors. About 27 adults whose cancer has progressed after prior treatments will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Shanghai chest hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SCLC, EXTENSIVE STAGE